HRP20170242T4 - Dihidrat spoja benzotiofena i postupak za njegovu proizvodnju - Google Patents

Dihidrat spoja benzotiofena i postupak za njegovu proizvodnju Download PDF

Info

Publication number: HRP20170242T4
Authority: HR; Croatia
Prior art keywords: ppm; disorder; dihydrate; schizophrenia; treatment
Prior art date: 2012-04-23

Application number

HRP20170242TT

Other languages

English (en)

Croatian (hr)

Inventor

Hiroshi Yamashita

Tetsuya Sato

Takuya MINOWA

Yusuke HOSHIKA

Hidekazu Toyobuku

Tatsuya Yamaguchi

Masahiro Sota

Shuuji KAWANO

Takayuki Nakamura

Ryohei ETO

Takuma IKEBUCHI

Kei Moriyama

Nobuaki Ito

Original Assignee

Otsuka Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-23

Filing date

2013-04-23

Publication date

2024-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170242(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-23 Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.

2017-04-07 Publication of HRP20170242T1 publication Critical patent/HRP20170242T1/hr

2017-09-22 Publication of HRP20170242T8 publication Critical patent/HRP20170242T8/hr

2024-03-01 Publication of HRP20170242T4 publication Critical patent/HRP20170242T4/hr

Links

150000004683 dihydrates Chemical class 0.000 title claims 11
-1 benzothiophene compound Chemical class 0.000 title claims 2
238000000034 method Methods 0.000 title claims 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title claims 2
201000000980 schizophrenia Diseases 0.000 claims 6
208000028698 Cognitive impairment Diseases 0.000 claims 5
208000010877 cognitive disease Diseases 0.000 claims 5
208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 3
208000024714 major depressive disease Diseases 0.000 claims 3
208000020401 Depressive disease Diseases 0.000 claims 2
ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 2
210000003169 central nervous system Anatomy 0.000 claims 2
150000001875 compounds Chemical class 0.000 claims 2
230000006806 disease prevention Effects 0.000 claims 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 2
208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 2
QNAKJJHSWWWWKD-UHFFFAOYSA-N 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one;dihydrate Chemical compound O.O.C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 QNAKJJHSWWWWKD-UHFFFAOYSA-N 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000007415 Anhedonia Diseases 0.000 claims 1
208000019901 Anxiety disease Diseases 0.000 claims 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
206010003805 Autism Diseases 0.000 claims 1
208000020706 Autistic disease Diseases 0.000 claims 1
208000020925 Bipolar disease Diseases 0.000 claims 1
208000027691 Conduct disease Diseases 0.000 claims 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
206010012218 Delirium Diseases 0.000 claims 1
206010012289 Dementia Diseases 0.000 claims 1
201000010374 Down Syndrome Diseases 0.000 claims 1
208000030814 Eating disease Diseases 0.000 claims 1
208000027534 Emotional disease Diseases 0.000 claims 1
208000019454 Feeding and Eating disease Diseases 0.000 claims 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
206010026749 Mania Diseases 0.000 claims 1
208000036626 Mental retardation Diseases 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
208000019022 Mood disease Diseases 0.000 claims 1
208000008589 Obesity Diseases 0.000 claims 1
208000002193 Pain Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
208000028017 Psychotic disease Diseases 0.000 claims 1
238000001237 Raman spectrum Methods 0.000 claims 1
208000027520 Somatoform disease Diseases 0.000 claims 1
208000000323 Tourette Syndrome Diseases 0.000 claims 1
208000016620 Tourette disease Diseases 0.000 claims 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
206010047700 Vomiting Diseases 0.000 claims 1
238000000862 absorption spectrum Methods 0.000 claims 1
208000012826 adjustment disease Diseases 0.000 claims 1
230000002917 arthritic effect Effects 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
230000003542 behavioural effect Effects 0.000 claims 1
208000015114 central nervous system disease Diseases 0.000 claims 1
229910052802 copper Inorganic materials 0.000 claims 1
239000010949 copper Substances 0.000 claims 1
208000026725 cyclothymic disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
235000014632 disordered eating Nutrition 0.000 claims 1
208000018459 dissociative disease Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000024732 dysthymic disease Diseases 0.000 claims 1
201000003104 endogenous depression Diseases 0.000 claims 1
201000003995 melancholia Diseases 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
201000003152 motion sickness Diseases 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
238000000634 powder X-ray diffraction Methods 0.000 claims 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 1
230000005855 radiation Effects 0.000 claims 1
208000012201 sexual and gender identity disease Diseases 0.000 claims 1
208000015891 sexual disease Diseases 0.000 claims 1
208000019116 sleep disease Diseases 0.000 claims 1
208000020685 sleep-wake disease Diseases 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
208000024891 symptom Diseases 0.000 claims 1
208000016686 tic disease Diseases 0.000 claims 1
230000008673 vomiting Effects 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

HRP20170242TT 2012-04-23 2013-04-23 Dihidrat spoja benzotiofena i postupak za njegovu proizvodnju HRP20170242T4 (hr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261636920P	2012-04-23	2012-04-23
US201361791378P	2013-03-15	2013-03-15
EP13722129.7A EP2841431B2 (en)	2012-04-23	2013-04-23	Dihydrate of benzothiophene compound and process for producing the same
PCT/JP2013/062681 WO2013162046A1 (en)	2012-04-23	2013-04-23	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (3)

Publication Number	Publication Date
HRP20170242T1 HRP20170242T1 (hr)	2017-04-07
HRP20170242T8 HRP20170242T8 (hr)	2017-09-22
HRP20170242T4 true HRP20170242T4 (hr)	2024-03-01

Family

ID=48428584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20170242TT HRP20170242T4 (hr)	2012-04-23	2013-04-23	Dihidrat spoja benzotiofena i postupak za njegovu proizvodnju

Country Status (36)

Country	Link
US (5)	US9499525B2 (2)
EP (1)	EP2841431B2 (2)
JP (1)	JP5952917B2 (2)
KR (1)	KR102160395B1 (2)
CN (1)	CN104254530B (2)
AR (1)	AR090774A1 (2)
AU (1)	AU2013253372B2 (2)
BR (1)	BR112014026424B1 (2)
CA (1)	CA2870000C (2)
CO (1)	CO7111315A2 (2)
CY (1)	CY1119103T1 (2)
DK (1)	DK2841431T4 (2)
EA (1)	EA026541B1 (2)
ES (1)	ES2617881T5 (2)
FI (1)	FI2841431T4 (2)
HR (1)	HRP20170242T4 (2)
HU (1)	HUE031997T2 (2)
IL (1)	IL235044B (2)
IN (1)	IN2014DN08867A (2)
JO (1)	JO3325B1 (2)
LT (1)	LT2841431T (2)
ME (1)	ME02619B (2)
MX (1)	MX361723B (2)
MY (1)	MY170220A (2)
NZ (1)	NZ630260A (2)
PH (1)	PH12014502324A1 (2)
PL (1)	PL2841431T5 (2)
PT (1)	PT2841431T (2)
RS (1)	RS55742B2 (2)
SG (1)	SG11201406790VA (2)
SI (1)	SI2841431T2 (2)
SM (2)	SMT201700130T1 (2)
TW (1)	TWI562991B (2)
UA (1)	UA117456C2 (2)
WO (1)	WO2013162046A1 (2)
ZA (1)	ZA201407477B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
TWI562991B (en) *	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
CN112402421A (zh) *	2012-10-25	2021-02-26	大塚制药株式会社	含有依匹唑派或其盐的预防和/或治疗剂
EP3134090B1 (en)	2014-04-22	2019-06-05	Otsuka Pharmaceutical Co., Ltd.	Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104447723A (zh) *	2014-11-28	2015-03-25	瑞阳制药有限公司	7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) *	2015-05-19	2015-08-12	杭州新博思生物医药有限公司	A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) *	2015-12-16	2021-11-23	北京福元医药股份有限公司	一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en)	2015-12-17	2017-06-22	Assia Chemical Industries Ltd.	Solid state forms of brexpiprazole
US10464931B2 (en)	2015-12-28	2019-11-05	Honour (R&D)	Process for the preparation of Quinolin-2(1H)-one derivatives
JP2019059672A (ja) *	2015-12-28	2019-04-18	大日本住友製薬株式会社	治療抵抗性うつ病等の治療薬
EP3411370A1 (en)	2016-02-01	2018-12-12	Hexal AG	Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en)	2016-05-03	2017-11-09	Cadila Healthcare Limited	Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) *	2016-05-12	2017-11-21	上海奥博生物医药技术有限公司	一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) *	2016-05-31	2017-12-07	Cipla Limited	A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) *	2016-07-04	2016-12-07	山东川成医药股份有限公司	一种依匹唑派的精制方法
PL233778B1 (pl)	2016-07-19	2019-11-29	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US11123300B2 (en)	2016-08-16	2021-09-21	Hexal Ag	Immediate release tablet of a benzothiophene compound
US20200093821A1 (en)	2016-08-16	2020-03-26	Hexal Ag	Pharmaceutical Compositions of a Benzothiophene Compound
CN107936005A (zh) *	2016-10-13	2018-04-20	上海科胜药物研发有限公司	一种依匹哌唑新晶型ii及其制备方法
CN106699745A (zh) *	2016-12-14	2017-05-24	上海博志研新药物技术有限公司	一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
WO2018141886A1 (en)	2017-02-02	2018-08-09	Hexal Aktiengesellschaft	Crystalline brexpiprazole
EP3501506B1 (en)	2017-12-19	2019-10-09	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) *	2020-03-24	2020-07-24	石药集团中奇制药技术（石家庄）有限公司	一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) *	2020-12-31	2022-01-25	Lake O'hara Llc	Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) *	2021-02-16	2022-08-25	大塚製薬株式会社	非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) *	2021-10-18	2023-04-27	大塚製薬株式会社	ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
UA82561C2 (uk)	2003-10-23	2008-04-25	Оцука Фармасьютикалз Ко., Лтд.	Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
US20090198059A1 (en)	2004-09-13	2009-08-06	Chava Satyanarayana	Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
JP4315393B2 (ja)	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
PE20090387A1 (es) *	2007-05-24	2009-04-28	Novartis Ag	Formulacion de pasireotida
CA2703742A1 (en) *	2007-10-26	2009-04-30	Repligen Corporation	Methods of identifying histone deacetylase inhibitors useful for neurological disorders
KR101921800B1 (ko) *	2008-01-30	2018-11-23	노파르티스 아게	옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
EP2233471A1 (en) *	2009-02-06	2010-09-29	Adamed Sp. z o.o.	A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process
NZ603076A (en)	2010-08-24	2014-12-24	Otsuka Pharma Co Ltd	Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
HUE065359T2 (hu) *	2011-03-18	2024-05-28	Alkermes Pharma Ireland Ltd	Szorbitán-észtereket tartalmazó gyógyászati készítmények
JP2012232958A (ja) *	2011-05-09	2012-11-29	Otsuka Pharmaceut Co Ltd	注射製剤
JP5832558B2 (ja) *	2011-07-28	2015-12-16	大塚製薬株式会社	ベンゾ［ｂ］チオフェン化合物の製造方法
JO3227B1 (ar) *	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
JOP20200109A1 (ar) *	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
TWI562991B (en) *	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

2013
- 2013-04-19 TW TW102114005A patent/TWI562991B/zh active
- 2013-04-22 AR ARP130101319A patent/AR090774A1/es unknown
- 2013-04-23 CN CN201380021622.6A patent/CN104254530B/zh active Active
- 2013-04-23 UA UAA201412555A patent/UA117456C2/uk unknown
- 2013-04-23 PT PT137221297T patent/PT2841431T/pt unknown
- 2013-04-23 PL PL13722129.7T patent/PL2841431T5/pl unknown
- 2013-04-23 HU HUE13722129A patent/HUE031997T2/en unknown
- 2013-04-23 FI FIEP13722129.7T patent/FI2841431T4/fi active
- 2013-04-23 LT LTEP13722129.7T patent/LT2841431T/lt unknown
- 2013-04-23 IN IN8867DEN2014 patent/IN2014DN08867A/en unknown
- 2013-04-23 WO PCT/JP2013/062681 patent/WO2013162046A1/en not_active Ceased
- 2013-04-23 JP JP2014550214A patent/JP5952917B2/ja active Active
- 2013-04-23 EA EA201491933A patent/EA026541B1/ru not_active IP Right Cessation
- 2013-04-23 US US14/396,224 patent/US9499525B2/en active Active
- 2013-04-23 KR KR1020147032745A patent/KR102160395B1/ko active Active
- 2013-04-23 BR BR112014026424-4A patent/BR112014026424B1/pt active IP Right Grant
- 2013-04-23 JO JOP/2013/0114A patent/JO3325B1/ar active
- 2013-04-23 SI SI201330538T patent/SI2841431T2/sl unknown
- 2013-04-23 HR HRP20170242TT patent/HRP20170242T4/hr unknown
- 2013-04-23 ES ES13722129T patent/ES2617881T5/es active Active
- 2013-04-23 NZ NZ630260A patent/NZ630260A/en unknown
- 2013-04-23 DK DK13722129.7T patent/DK2841431T4/da active
- 2013-04-23 CA CA2870000A patent/CA2870000C/en active Active
- 2013-04-23 ME MEP-2017-56A patent/ME02619B/me unknown
- 2013-04-23 RS RS20170214A patent/RS55742B2/sr unknown
- 2013-04-23 MY MYPI2014703139A patent/MY170220A/en unknown
- 2013-04-23 EP EP13722129.7A patent/EP2841431B2/en active Active
- 2013-04-23 SG SG11201406790VA patent/SG11201406790VA/en unknown
- 2013-04-23 AU AU2013253372A patent/AU2013253372B2/en active Active
- 2013-04-23 SM SM20170130T patent/SMT201700130T1/it unknown
- 2013-04-23 MX MX2014012527A patent/MX361723B/es active IP Right Grant
2014
- 2014-10-07 IL IL235044A patent/IL235044B/en active IP Right Grant
- 2014-10-14 CO CO14226629A patent/CO7111315A2/es unknown
- 2014-10-15 ZA ZA2014/07477A patent/ZA201407477B/en unknown
- 2014-10-17 PH PH12014502324A patent/PH12014502324A1/en unknown
2016
- 2016-10-14 US US15/294,644 patent/US10407415B2/en active Active
2017
- 2017-02-28 SM SM201700130T patent/SMT201700130B/it unknown
- 2017-03-07 CY CY20171100293T patent/CY1119103T1/el unknown
2019
- 2019-09-09 US US16/564,972 patent/US20200140424A1/en not_active Abandoned
2020
- 2020-08-04 US US16/985,177 patent/US20210115030A1/en not_active Abandoned
2022
- 2022-02-14 US US17/651,042 patent/US20230049327A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR102160395B1 (ko)	2020-09-28
PT2841431T (pt)	2017-03-07
SMT201700130B (it)	2017-03-08
SI2841431T1 (sl)	2017-03-31
FI2841431T4 (fi)	2024-04-18
US20230049327A1 (en)	2023-02-16
EP2841431B1 (en)	2017-01-04
PL2841431T5 (pl)	2024-07-15
IL235044A0 (en)	2014-12-31
HRP20170242T8 (hr)	2017-09-22
TW201348229A (zh)	2013-12-01
CA2870000C (en)	2021-02-16
US20200140424A1 (en)	2020-05-07
SMT201700130T1 (it)	2017-03-08
MY170220A (en)	2019-07-10
DK2841431T4 (da)	2024-02-12
BR112014026424A2 (pt)	2017-06-27
ES2617881T5 (es)	2024-05-22
ZA201407477B (en)	2015-12-23
RS55742B1 (sr)	2017-07-31
PL2841431T3 (pl)	2017-06-30
NZ630260A (en)	2015-09-25
US20210115030A1 (en)	2021-04-22
DK2841431T3 (en)	2017-03-06
HUE031997T2 (en)	2017-08-28
EP2841431A1 (en)	2015-03-04
TWI562991B (en)	2016-12-21
AR090774A1 (es)	2014-12-03
WO2013162046A1 (en)	2013-10-31
CO7111315A2 (es)	2014-11-10
CN104254530B (zh)	2016-09-21
ME02619B (me)	2017-06-20
MX2014012527A (es)	2015-03-19
US20170066752A1 (en)	2017-03-09
JO3325B1 (ar)	2019-03-13
IL235044B (en)	2019-05-30
SI2841431T2 (sl)	2024-03-29
EP2841431B2 (en)	2024-01-24
IN2014DN08867A (2)	2015-05-22
UA117456C2 (uk)	2018-08-10
ES2617881T3 (es)	2017-06-20
EA026541B1 (ru)	2017-04-28
SG11201406790VA (en)	2014-11-27
JP5952917B2 (ja)	2016-07-13
LT2841431T (lt)	2017-03-27
EA201491933A1 (ru)	2015-03-31
CN104254530A (zh)	2014-12-31
CY1119103T1 (el)	2018-02-14
HRP20170242T1 (hr)	2017-04-07
KR20150013189A (ko)	2015-02-04
AU2013253372B2 (en)	2016-12-08
US20150087655A1 (en)	2015-03-26
PH12014502324B1 (en)	2015-01-12
PH12014502324A1 (en)	2015-01-12
RS55742B2 (sr)	2024-04-30
JP2015514677A (ja)	2015-05-21
US9499525B2 (en)	2016-11-22
US10407415B2 (en)	2019-09-10
BR112014026424B1 (pt)	2022-09-13
CA2870000A1 (en)	2013-10-31
AU2013253372A1 (en)	2014-10-30
MX361723B (es)	2018-12-14
HK1203073A1 (en)	2015-10-16

Publication	Publication Date	Title
HRP20170242T4 (hr)	2024-03-01	Dihidrat spoja benzotiofena i postupak za njegovu proizvodnju
JP2015514677A5 (2)	2016-04-07
JP2014526435A5 (2)	2015-10-29
NZ600008A (en)	2014-10-31	Multicyclic compounds and methods of use thereof
CO6321133A2 (es)	2011-09-20	Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns
ECSP077166A (es)	2007-02-28	Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns)
NZ603230A (en)	2013-09-27	Nitrogen containing heteroaryl compounds
AR067772A1 (es)	2009-10-21	Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
WO2014106238A8 (en)	2015-06-11	Heterocyclic compounds and methods of use thereof
NZ705135A (en)	2017-10-27	Heteroaryl compounds and methods of use thereof
MA32898B1 (fr)	2011-12-01	Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
WO2012096929A3 (en)	2012-10-11	Heteroaryl compounds and methods of use thereof
MD20150037A2 (ro)	2015-11-30	Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
UA105187C2 (uk)	2014-04-25	Похідне 7-піперидиналкіл-3,4-дигідрохінолону
EP3287454B1 (en)	2020-09-02	Heterocyclic compound
HRP20171772T1 (hr)	2017-12-29	Kristalični oblik soli od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona koji služi kao antagonist receptora oreksina
MX2009005509A (es)	2009-06-03	2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
MX2015014353A (es)	2016-04-07	Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
JP2019511548A5 (2)	2021-05-20
MX363632B (es)	2019-03-29	Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
CL2007002768A1 (es)	2008-04-18	Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki
EA200970596A1 (ru)	2010-02-26	Соединения с сочетанием антагонистической активности в отношении каннабиноидных рецепторов сви ингибирующей активности в отношении ацетилхолинэстеразы
NZ702239A (en)	2017-01-27	Heteroaryl compounds and methods of use thereof
MX377195B (es)	2025-03-07	Derivados de morfolina-piridina.
Jafari et al.	2012	Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio